However, in summary, the well-powered studies that take in the full range of AD from preclinical to MCI and dementia stages seem to demonstrate that AD-related PRSs are associated with biomarker changes reflecting both abnormal tau and Aβ metabolism. The gene discussed is MAPT; the disease is dementia.